Why do Americans often pay far more for the same prescription drugs than people in other wealthy countries?

In this episode of Reimagine Healthcare, Noah Volz breaks down one of the most distorted parts of the American healthcare system: prescription drug pricing.

The episode starts with a simple image: a tube of toothpaste with both ends open. Countries like Canada, the United Kingdom, Germany, and France use national purchasing power, price regulation, or formal negotiation to push drug prices down. They clamp one end of the tube. The United States mostly does not. So when manufacturers look for the market that can absorb the highest prices, the pressure often comes out here.

That means drug pricing is not just a national policy issue. It shows up in your deductible, your employer’s renewal notice, your pharmacy-counter conversation, and the coverage decisions made by public programs that serve Southern Oregon.

This episode explains:

• Why U.S. drug prices are so much higher than prices in peer countries
• How Medicare Part D changed prescription drug coverage
• Why Medicare was blocked from broad drug-price negotiation for years
• What pharmacy benefit managers, or PBMs, actually do
• How rebates can reward high sticker prices
• Why patients with high deductibles or coinsurance can be hit hardest
• Why GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound expose the system’s contradictions
• How drug costs affect Southern Oregon families, employers, Medicaid programs, and local budgets

The episode also offers practical questions for patients, clinicians, employers, and policy-minded listeners.

The main takeaway is simple: the price of a drug is not just a number. It is the output of a system.

And if that system keeps producing unaffordable access, rising premiums, and public confusion, we should stop pretending it is normal.

Subscribe at reimagine-healthcare.org for plain-English healthcare analysis rooted in Southern Oregon.

This podcast is for educational purposes only and is not medical advice.